{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T03:37:52Z","timestamp":1769398672146,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00520-022-07353-3","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T16:22:04Z","timestamp":1662654124000},"page":"9317-9327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-0265","authenticated-orcid":false,"given":"Hartmut","family":"Link","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Meise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Maas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamen","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"7353_CR1","doi-asserted-by":"publisher","unstructured":"Klastersky J, de Naurois J, Rolston K et al (2016) ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","DOI":"10.1093\/annonc\/mdw325"},{"issue":"10","key":"7353_CR2","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475\u20132484. https:\/\/doi.org\/10.1093\/annonc\/mdt226","journal-title":"Ann Oncol"},{"key":"7353_CR3","unstructured":"National Cancer Institute. Common terminology criteria for adverse advents v4.03 (Excel). June 14, 2010. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"issue":"28","key":"7353_CR4","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"7353_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"issue":"11","key":"7353_CR6","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00520-017-3842-1","volume":"25","author":"M Aapro","year":"2017","unstructured":"Aapro M, Boccia R, Leonard R et al (2017) Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer 25(11):3295\u20133304. https:\/\/doi.org\/10.1007\/s00520-017-3842-1","journal-title":"Support Care Cancer"},{"key":"7353_CR7","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hematopoietic Growth Factors. Version 4, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf"},{"issue":"1","key":"7353_CR8","doi-asserted-by":"publisher","first-page":"15374","DOI":"10.1038\/s41598-019-51982-4","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Chen L, Liu F et al (2019) Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis. Sci Rep 9(1):15374. https:\/\/doi.org\/10.1038\/s41598-019-51982-4","journal-title":"Sci Rep"},{"issue":"12","key":"7353_CR9","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1185\/03007995.2014.962131","volume":"30","author":"A Buchner","year":"2014","unstructured":"Buchner A, Lammerich A, Abdolzade-Bavil A et al (2014) Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers. Curr Med Res Opin 30(12):2523\u20132533. https:\/\/doi.org\/10.1185\/03007995.2014.962131","journal-title":"Curr Med Res Opin"},{"key":"7353_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/1471-2407-13-386","volume":"13","author":"I Bondarenko","year":"2013","unstructured":"Bondarenko I, Gladkov OA, Elsaesser R et al (2013) Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy. BMC Cancer 13:386. https:\/\/doi.org\/10.1186\/1471-2407-13-386","journal-title":"BMC Cancer"},{"issue":"1","key":"7353_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00520-015-2803-9","volume":"24","author":"OA Gladkov","year":"2016","unstructured":"Gladkov OA, Buchner A, Bias P et al (2016) Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study. Support Care Cancer 24(1):395\u2013400. https:\/\/doi.org\/10.1007\/s00520-015-2803-9","journal-title":"Support Care Cancer"},{"key":"7353_CR12","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-020-05711-7","volume":"29","author":"H Link","year":"2021","unstructured":"Link H, Illerhaus G, Martens UM et al (2021) Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer 29:2519\u20132527. https:\/\/doi.org\/10.1007\/s00520-020-05711-7","journal-title":"Support Care Cancer"},{"key":"7353_CR13","unstructured":"Statistisches Bundesamt DESTATIS. Ergebnisse der Bev\u00f6lkerungsfortschreibung auf Grundlage des Zensus 2011 [April 30, 2021]. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/liste-zensus-geschlecht-staatsangehoerigkeit.html"},{"key":"7353_CR14","unstructured":"Bundesministerium f\u00fcr Gesundheit. Kennzahlen der Gesetzlichen Krankenversicherung\u00a02007\u00a0bis\u00a02020. Kennzahlen und Faustformeln, https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Kennzahlen_Daten\/KF2021Bund_Juli_2021.pdf"},{"issue":"1","key":"7353_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J (2016) Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf 25(1):106\u2013109. https:\/\/doi.org\/10.1002\/pds.3895","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"7353_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"key":"7353_CR17","unstructured":"The International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification (ICD-10-GM). https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/ICD\/ICD-10-GM\/_node.html"},{"key":"7353_CR18","doi-asserted-by":"publisher","unstructured":"Link H, Kerkmann M, Holtmann L, Ortner P (2019) Working Groups Supportive C, Medical Oncology within the German Cancer S. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer 27(4):1459\u20131469. https:\/\/doi.org\/10.1007\/s00520-018-4481-x","DOI":"10.1007\/s00520-018-4481-x"},{"key":"7353_CR19","unstructured":"Einheitlicher Bewertungsma\u00dfstab. https:\/\/www.kbv.de\/html\/online-ebm.php"},{"issue":"11","key":"7353_CR20","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Baser O, Kutikova L et al (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 23(11):3131\u20133140. https:\/\/doi.org\/10.1007\/s00520-015-2686-9","journal-title":"Support Care Cancer"},{"key":"7353_CR21","doi-asserted-by":"publisher","first-page":"A434","DOI":"10.1016\/j.jval.2015.09.1041","volume":"18","author":"TC Bond","year":"2015","unstructured":"Bond TC, Mueller U, Barnes G et al (2015) Lipegfilgrastim for reduction of chemotherapy-induced neutropenia related events: a meta-analysis. Value Health 18:A434. https:\/\/doi.org\/10.1016\/j.jval.2015.09.1041","journal-title":"Value Health"},{"issue":"5","key":"7353_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000381631","volume":"38","author":"CM Kurbacher","year":"2015","unstructured":"Kurbacher CM, Fietz T, Diel IJ et al (2015) NADIR: A non-interventional study on the prophylaxis of chemotherapy-induced neutropenia using lipegfilgrastim \u2013 first interim analysis. Oncol Res Treat 38(5):221\u2013229. https:\/\/doi.org\/10.1159\/000381631","journal-title":"Oncol Res Treat"},{"key":"7353_CR23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fphar.2017.00614","volume":"8","author":"EIH Akpo","year":"2017","unstructured":"Akpo EIH, Jansen IR, Maes E, Simoens S (2017) Cost-utility analysis of lipegfilgrastim compared to pegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in patients with stage ii\u2013iv breast cancer. Front Pharmacol 8:614","journal-title":"Front Pharmacol"},{"issue":"6","key":"7353_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s12282-018-0872-6","volume":"25","author":"L Gao","year":"2018","unstructured":"Gao L, Li SC (2018) Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation. Breast Cancer 25(6):671\u2013680","journal-title":"Breast Cancer"},{"issue":"1","key":"7353_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00520-015-2779-5","volume":"24","author":"H Link","year":"2016","unstructured":"Link H, Nietsch J, Kerkmann M, Ortner P (2016) Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy\u2013a representative sample survey in Germany. Support Care Cancer 24(1):367\u2013376. https:\/\/doi.org\/10.1007\/s00520-015-2779-5","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07353-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07353-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07353-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T10:49:14Z","timestamp":1667472554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07353-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7353"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07353-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No ethical approval and consent were necessary as this is a retrospective database study based on anonymized claims data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have given their approval for publication. Only fully anonymized data were used.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HL declares to have received personal fees from Accord Healthcare Limited, Europharma, Johnson & Johnson, Lindis-Blood Care, Mundipharma, Onkodin GmbH (onchemo.com), Pharmacosmos, Rhineland-Palatinate Medical Association (Mainz), Samsung Bioepis; SAP, Servier Deutschland GmbH, Shire Deutschland GmbH (Takeda Group), SIGAL SMS GmbH, Takeda, Hogg Robinson Germany, Teva, and Viatris. SF, MT, and SD are employees of Teva. JSH, DM, and CM are employees of Xcenda GmbH. Xcenda GmbH received consulting fees for the conduct of the analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}